scholarly journals CD44-Targeting Oxygen Self-Sufficient Nanoparticles for Enhanced Photodynamic Therapy Against Malignant Melanoma

2020 ◽  
Vol Volume 15 ◽  
pp. 10401-10416
Author(s):  
Xiaoyang Hou ◽  
Yingkai Tao ◽  
Xinxin Li ◽  
Yanyu Pang ◽  
Chunsheng Yang ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Melanoma ◽  
Cd44 Targeting

Natural Hydrogels Applied in Photodynamic Therapy

2020 ◽  
Vol 27 (16) ◽  
pp. 2681-2703 ◽  
Author(s):  
Zhipan Feng ◽  
Shiying Lin ◽  
Andrew McDonagh ◽  
Chen Yu
Keyword(s):  
Photodynamic Therapy ◽  
Hyaluronic Acid ◽  
Drug Release ◽  
Three Dimensional ◽  
Controlled Drug Release ◽  
Natural Polymers ◽  
Current Review ◽  
Design Variables ◽  
Cd44 Targeting

Natural hydrogels are three-dimensional (3D) water-retaining materials with a skeleton consisting of natural polymers, their derivatives or mixtures. Natural hydrogels can provide sustained or controlled drug release and possess some unique properties of natural polymers, such as biodegradability, biocompatibility and some additional functions, such as CD44 targeting of hyaluronic acid. Natural hydrogels can be used with photosensitizers (PSs) in photodynamic therapy (PDT) to increase the range of applications. In the current review, the pertinent design variables are discussed along with a description of the categories of natural hydrogels available for PDT.

Rational design of a lysosome-targeting and near-infrared absorbing Ru(ii)–BODIPY conjugate for photodynamic therapy

2021 ◽  
Vol 57 (14) ◽  
pp. 1790-1793
Author(s):  
Liping Qiao ◽  
Jiangping Liu ◽  
Yunhong Han ◽  
Fangmian Wei ◽  
Xinxing Liao ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Melanoma ◽  
Rational Design ◽  
Near Infrared ◽  
Inhibitory Efficiency ◽  
A375 Cells

A lysosome-targeting and near-infrared absorbing Ru(ii)–BODIPY conjugate exhibits prominent tumor inhibitory efficiency in malignant melanoma A375 cells and in vivo experiments.

In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma

1998 ◽  
Vol 5 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Riad Haddad ◽  
Amir Blumenfeld ◽  
Annette Siegal ◽  
Ofer Kaplan ◽  
Meir Cohen ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Melanoma ◽  
In Vivo Effects

scholarly journals Novel sulfonamide porphyrin TBPoS-2OH used in photodynamic therapy for malignant melanoma

2021 ◽  
Vol 133 ◽  
pp. 111042
Author(s):  
Zhaohai Pan ◽  
Jiaojiao Fan ◽  
Qi Xie ◽  
Xin Zhang ◽  
Wen Zhang ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Melanoma

scholarly journals Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2432
Author(s):  
Hye Suk Hwang ◽  
Kondareddy Cherukula ◽  
Yong Jun Bang ◽  
Veena Vijayan ◽  
Myeong Ju Moon ◽  
...  
Keyword(s):  
T Cells ◽  
Photodynamic Therapy ◽  
Malignant Melanoma ◽  
Combination Therapy ◽  
Cd8 T Cells ◽  
Tumor Antigen ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitor ◽  
Tumor Ablation ◽  
Effector Memory

Immune checkpoint inhibitors become a standard therapy for malignant melanoma. As immune checkpoint inhibitor monotherapies proved to have limited efficacy in significant portion of patients, it is envisaged that combination with other therapeutic modalities may improve clinical outcomes. We investigated the effect of combining photodynamic therapy (PDT) and TLR5 agonist flagellin-adjuvanted tumor-specific peptide vaccination (FlaB-Vax) on the promotion of PD-1 blockade-mediated melanoma suppression using a mouse B16-F10 implantation model. Using a bilateral mouse melanoma cancer model, we evaluated the potentiation of PD-1 blockade by the combination of peritumoral FlaB-Vax delivery and PDT tumor ablation. A photosensitizing agent, pheophorbide A (PhA), was used for laser-triggered photodynamic destruction of the primary tumor. The effect of combination therapy in conjunction with PD-1 blockade was evaluated for tumor growth and survival. The effector cytokines that promote the activation of CD8+ T cells and antigen-presenting cells in tumor tissue and tumor-draining lymph nodes (TDLNs) were also assayed. PDT and FlaB-Vax combination therapy induced efficacious systemic antitumor immune responses for local and abscopal tumor control, with a significant increase in tumor-infiltrating effector memory CD8+ T cells and systemic IFNγ secretion. The combination of PDT and FlaB-Vax also enhanced the infiltration of tumor antigen-reactive CD8+ T cells and the accumulation of migratory CXCL10-secreting CD103+ dendritic cells (DCs) presumably contributing to tumor antigen cross-presentation in the tumor microenvironment (TME). The CD8+ T-cell-dependent therapeutic benefits of PDT combined with FlaB-Vax was significantly enhanced by a PD-1-targeting checkpoint inhibitor therapy. Conclusively, the combination of FlaB-Vax with PDT-mediated tumor ablation would serve a safe and feasible combinatorial therapy for enhancing PD-1 blockade treatment of malignant melanoma.

Sign in / Sign up

Export Citation Format

Share Document